CLINICAL TRIAL SUMMARY

MDACC Study No:2011-0705 (clinicaltrials.gov NCT No: NCT01582152)
Title:Phase I/II Adaptive Randomized Trial of Bevacizumab versus Bevacizumab plus TPI 287 in Adults with Recurrent Glioblastoma
Principal Investigator:Charles A. Conrad
Treatment Agent:Bevacizumab; TPI 287
Study Status:Open
Study Description:The goal of Part I of this clinical research study is to find the highest
tolerable dose of TPI 287 that can be given with bevacizumab to patients with
glioblastoma. The goal of Part II is to learn if TPI 287 when given with
bevacizumab can help to control glioblastoma better than when bevacizumab is
given alone. The safety of the drug combination will also be studied.

TPI 287 is similar to a type of chemotherapy drug called a taxane and is
designed to block a protein (tubulin) that helps the cancer cells divide. By
blocking the tubulin, the drug may be able to cause the cancer cells to shrink
or stop growing.

Bevacizumab is designed to prevent or slow down the growth of cancer cells by
blocking the growth of blood vessels.

Hide details for General InformationGeneral Information

Disease Group:Brain; CNS
Phase of Study:Phase I/Phase II
Treatment Agents:Bevacizumab
TPI 287
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Archer Biosciences, Inc.
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Charles A. Conrad
Dept:Neuro Oncology
For Clinical Trial Enrollment:713-792-2883
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults